News
CELZ
2.053
+3.19%
0.063
Weekly Report: what happened at CELZ last week (0323-0327)?
Weekly Report · 4d ago
Weekly Report: what happened at CELZ last week (0316-0320)?
Weekly Report · 03/23 10:09
Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000
Reuters · 03/20 20:46
Weekly Report: what happened at CELZ last week (0309-0313)?
Weekly Report · 03/16 10:09
Weekly Report: what happened at CELZ last week (0302-0306)?
Weekly Report · 03/09 10:09
Weekly Report: what happened at CELZ last week (0223-0227)?
Weekly Report · 03/02 10:09
Weekly Report: what happened at CELZ last week (0216-0220)?
Weekly Report · 02/23 10:09
Weekly Report: what happened at CELZ last week (0209-0213)?
Weekly Report · 02/16 10:09
CREATIVE MEDICAL TECHNOLOGY HOLDINGS ACHIEVES SECOND WHO INN MILESTONE, STRENGTHENING GLOBAL REGULATORY POSITIONING ACROSS EXPANDING CELL THERAPY PIPELINE
Reuters · 02/10 14:14
Creative Medical achieves second WHO INN milestone
TipRanks · 02/10 14:06
Creative Medical Technology Holdings Achieves Second WHO INN Milestone for Cell Therapy Pipeline
Reuters · 02/10 14:00
Weekly Report: what happened at CELZ last week (0202-0206)?
Weekly Report · 02/09 10:10
Weekly Report: what happened at CELZ last week (0126-0130)?
Weekly Report · 02/02 10:10
Weekly Report: what happened at CELZ last week (0119-0123)?
Weekly Report · 01/26 10:09
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/20 12:05
Weekly Report: what happened at CELZ last week (0112-0116)?
Weekly Report · 01/19 10:15
Creative Medical's ADAPT Trial In Chronic Lower Back Pain Shows Functional And Pain Improvements
NASDAQ · 01/13 15:50
Creative Medical announces interim data from ADAPT trial of CELZ-201
TipRanks · 01/13 14:25
Creative Medical Announces Interim 180-Day Follow-Up Data From FDA-Cleared ADAPT Clinical Trial Evaluating CELZ-201, Proprietary Perinatal Tissue-Derived Cell Therapy For Chronic Lower Back Pain
Benzinga · 01/13 14:17
Creative Medical Technology Reports Positive Interim Results for CELZ-201 in Chronic Lower Back Pain Trial
Reuters · 01/13 14:15
More
Webull provides a variety of real-time CELZ stock news. You can receive the latest news about Creative Med Technology Hldgs through multiple platforms. This information may help you make smarter investment decisions.
About CELZ
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.